JP7239566B2 - グルカゴン様ペプチド１受容体アゴニストおよびそれらの使用 - Google Patents

グルカゴン様ペプチド１受容体アゴニストおよびそれらの使用 Download PDF

Info

Publication number
JP7239566B2
JP7239566B2 JP2020516667A JP2020516667A JP7239566B2 JP 7239566 B2 JP7239566 B2 JP 7239566B2 JP 2020516667 A JP2020516667 A JP 2020516667A JP 2020516667 A JP2020516667 A JP 2020516667A JP 7239566 B2 JP7239566 B2 JP 7239566B2
Authority
JP
Japan
Prior art keywords
glp1
disease
antigen
pharmaceutical composition
glp1 receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020516667A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020534016A (ja
Inventor
ヤン・ウェイ
ハルカ・オカモト
ジェスパー・グロマーダ
サミュエル・デーヴィス
アンドリュー・ジェイ・マーフィー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Publication of JP2020534016A publication Critical patent/JP2020534016A/ja
Priority to JP2023030635A priority Critical patent/JP7559112B2/ja
Application granted granted Critical
Publication of JP7239566B2 publication Critical patent/JP7239566B2/ja
Priority to JP2024159697A priority patent/JP7789871B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • C07K16/082—Hepadnaviridae, e.g. hepatitis B virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Neurology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
JP2020516667A 2017-09-22 2018-09-21 グルカゴン様ペプチド１受容体アゴニストおよびそれらの使用 Active JP7239566B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023030635A JP7559112B2 (ja) 2017-09-22 2023-03-01 グルカゴン様ペプチド１受容体アゴニストおよびそれらの使用
JP2024159697A JP7789871B2 (ja) 2017-09-22 2024-09-17 グルカゴン様ペプチド１受容体アゴニストおよびそれらの使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762562283P 2017-09-22 2017-09-22
US62/562,283 2017-09-22
PCT/US2018/052110 WO2019060653A1 (en) 2017-09-22 2018-09-21 GLP-1 RECEPTOR AGONISTS (GLUCAGON-LIKE PEPTIDE 1) AND USES THEREOF

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023030635A Division JP7559112B2 (ja) 2017-09-22 2023-03-01 グルカゴン様ペプチド１受容体アゴニストおよびそれらの使用

Publications (2)

Publication Number Publication Date
JP2020534016A JP2020534016A (ja) 2020-11-26
JP7239566B2 true JP7239566B2 (ja) 2023-03-14

Family

ID=63799082

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020516667A Active JP7239566B2 (ja) 2017-09-22 2018-09-21 グルカゴン様ペプチド１受容体アゴニストおよびそれらの使用
JP2023030635A Active JP7559112B2 (ja) 2017-09-22 2023-03-01 グルカゴン様ペプチド１受容体アゴニストおよびそれらの使用
JP2024159697A Active JP7789871B2 (ja) 2017-09-22 2024-09-17 グルカゴン様ペプチド１受容体アゴニストおよびそれらの使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023030635A Active JP7559112B2 (ja) 2017-09-22 2023-03-01 グルカゴン様ペプチド１受容体アゴニストおよびそれらの使用
JP2024159697A Active JP7789871B2 (ja) 2017-09-22 2024-09-17 グルカゴン様ペプチド１受容体アゴニストおよびそれらの使用

Country Status (14)

Country Link
US (4) US11045522B2 (enExample)
EP (1) EP3684793A1 (enExample)
JP (3) JP7239566B2 (enExample)
KR (1) KR102696518B1 (enExample)
CN (2) CN118955732A (enExample)
AU (2) AU2018338178B2 (enExample)
CA (1) CA3073964A1 (enExample)
EA (1) EA202090649A1 (enExample)
IL (2) IL273253B2 (enExample)
MX (1) MX2020002977A (enExample)
MY (2) MY207828A (enExample)
SG (1) SG11202001637PA (enExample)
WO (1) WO2019060653A1 (enExample)
ZA (1) ZA202001167B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023071827A (ja) * 2017-09-22 2023-05-23 リジェネロン・ファーマシューティカルズ・インコーポレイテッド グルカゴン様ペプチド１受容体アゴニストおよびそれらの使用

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12122817B2 (en) * 2020-09-22 2024-10-22 Serpentide Inc. Long-lasting GLP1 analogue drug for type-2 diabetes
CN116670171A (zh) * 2020-12-03 2023-08-29 免疫新炉有限公司 包括glp-1受体激动剂和抗oscar抗体的融合蛋白及其用途
WO2022117044A1 (en) * 2020-12-03 2022-06-09 Sunshine Lake Pharma Co., Ltd. Glp-1/gcg dual receptor agonist polypeptide and fusion protein thereof
CN112716966B (zh) * 2021-02-03 2022-05-03 浙江诺得药业有限公司 一种恩格列净药用组合物及其制备方法
CN113461785B (zh) * 2021-04-13 2022-10-14 湖南中晟全肽生化有限公司 Glp-1受体激动剂及其应用
CN119638849A (zh) * 2021-10-18 2025-03-18 深圳科兴药业有限公司 一种生长激素融合蛋白及其应用
CN114788876B (zh) * 2022-02-24 2024-07-05 北京医院 治疗糖尿病的mRNA药物制剂及其制备方法与应用
US20250289861A1 (en) * 2022-05-04 2025-09-18 Immunoforge Co.,Ltd. Fusion protein comprising glp-1, immunoglobulin fc, and igf-1 and use thereof
WO2024123812A1 (en) 2022-12-05 2024-06-13 Shattuck Labs, Inc. Fusion proteins for the treatment of cardiometabolic diseases
CN117143242B (zh) * 2023-10-30 2024-03-29 南京佰抗生物科技有限公司 抗Galectin-3蛋白的单克隆抗体组合物及应用
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof
US20250270274A1 (en) * 2024-02-26 2025-08-28 Serpentide Inc. Super long-lasting glp1 or glp1/gip analogue drug for type-2 diabetes and obesity

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101229610B1 (ko) 2009-10-09 2013-02-05 한남대학교 산학협력단 Ｇｌｐ-1 유사체의 융합체, 및 이를 유효성분으로 함유하는 당뇨병의 예방 또는 치료용 조성물
JP2016532448A (ja) 2013-08-13 2016-10-20 ジーエムエーエックス バイオファーム エルエルシー． Ｇｌｐ−１ｒに特異的に結合する抗体およびそのｇｌｐ−１との融合タンパク質
JP2019525732A (ja) 2016-06-09 2019-09-12 メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ プロテアーゼ耐性一脂質付加ペプチド

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004251145C1 (en) 2003-06-12 2011-04-14 Eli Lilly And Company GLP-1 analog fusion proteins
US8257740B1 (en) 2011-08-15 2012-09-04 Gp Medical, Inc. Pharmaceutical composition of nanoparticles
US20060275288A1 (en) 2005-01-20 2006-12-07 Grihalde Nelson D GLP-1 receptor agonist and allosteric modulator monoclonal antibodies and uses thereof
US8246995B2 (en) 2005-05-10 2012-08-21 The Board Of Trustees Of The Leland Stanford Junior University Hydrophobic nanotubes and nanoparticles as transporters for the delivery of drugs into cells
US8497240B2 (en) 2006-08-17 2013-07-30 Amylin Pharmaceuticals, Llc DPP-IV resistant GIP hybrid polypeptides with selectable properties
AR064623A1 (es) 2006-12-21 2009-04-15 Centocor Inc Uso de agonistas del receptor de glp -1 de accion prolongada para mejorar la sensibilidad a la insulina y los perfiles lipidicos
WO2009020802A2 (en) 2007-08-03 2009-02-12 Eli Lilly And Company Treatment for obesity
EP2190872B1 (en) 2007-09-05 2018-03-14 Novo Nordisk A/S Glucagon-like peptide-1 derivatives and their pharmaceutical use
LT2373681T (lt) 2008-12-10 2017-04-10 Glaxosmithkline Llc Albiglutido farmacinės kompozicijos
US20120148586A1 (en) 2009-08-27 2012-06-14 Joyce Ching Tsu Chou Glucagon-like protein-1 receptor (glp-1r) agonists for treating autoimmune disorders
WO2011056644A2 (en) 2009-10-28 2011-05-12 Centocor Ortho Biotech Inc. Anti-glp-1r antibodies and their uses
US20120294855A1 (en) 2009-11-03 2012-11-22 Eli Lilly & Company Glp-1 receptor agonist compounds for obstructive sleep apnea
SG11201500682WA (en) 2012-09-07 2015-02-27 Sanofi Sa Fusion proteins for treating a metabolic syndrome
ES2687083T3 (es) 2013-01-17 2018-10-23 Vtv Therapeutics Llc Combinaciones de un agonista del GLPR1 y metformina y el uso de estos para el tratamiento de la diabetes tipo 2 y otros trastornos
US20150259416A1 (en) 2014-03-12 2015-09-17 Biocrine Ab Methods for treating and/or limiting development of diabetes
CN104098702B (zh) 2014-07-23 2017-06-16 湖北工业大学 一种利用mfh融合蛋白制备glp‑1多肽或其类似物方法和应用
CN106390100B (zh) * 2015-01-28 2021-06-22 中国科学院天津工业生物技术研究所 一种多肽复合物作为glp-1药物载体的应用、方法及其融合蛋白复合物
PL3257524T3 (pl) 2015-02-11 2021-03-08 Gmax Biopharm Llc Stabilny preparat farmaceutyczny w postaci roztworu białka fuzyjnego przeciwciała przeciwko glp-1r
TWI622596B (zh) 2015-10-26 2018-05-01 美國禮來大藥廠 升糖素受體促效劑
MY207828A (en) * 2017-09-22 2025-03-21 Regeneron Pharma Glucagon-like peptide 1 receptor agonists and uses thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101229610B1 (ko) 2009-10-09 2013-02-05 한남대학교 산학협력단 Ｇｌｐ-1 유사체의 융합체, 및 이를 유효성분으로 함유하는 당뇨병의 예방 또는 치료용 조성물
JP2016532448A (ja) 2013-08-13 2016-10-20 ジーエムエーエックス バイオファーム エルエルシー． Ｇｌｐ−１ｒに特異的に結合する抗体およびそのｇｌｐ−１との融合タンパク質
JP2019525732A (ja) 2016-06-09 2019-09-12 メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ プロテアーゼ耐性一脂質付加ペプチド

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Hye-Shin Chung et al.，The N-terminal alanine-extended GLP-1/IgG-Fc fusion protein confers resistance to DPP-IV and reduces serum glucose level in db/db mice，Regulatory Peptides，2011年，Vol.170，Issue 1-3，pp.1-3
Ji-Yeon Oh et al.，Novel DPP-IV-resistant Analogs of GLP-1: The N-terminal Extension of GLP-1 by a Single Amino Acid，Bulletin of the Korean Chemical Society，2009年，Vol.30，No.10，pp.2471-2474
Yong-Mo Kim et al.，Novel AGLP-1 albumin fusion protein as a long-lasting agent for type 2 diabetes，BMB Reports，2013年，Vol.46，Issue 12，pp.606-610

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023071827A (ja) * 2017-09-22 2023-05-23 リジェネロン・ファーマシューティカルズ・インコーポレイテッド グルカゴン様ペプチド１受容体アゴニストおよびそれらの使用
JP7559112B2 (ja) 2017-09-22 2024-10-01 リジェネロン・ファーマシューティカルズ・インコーポレイテッド グルカゴン様ペプチド１受容体アゴニストおよびそれらの使用
JP2024178255A (ja) * 2017-09-22 2024-12-24 リジェネロン・ファーマシューティカルズ・インコーポレイテッド グルカゴン様ペプチド１受容体アゴニストおよびそれらの使用
JP7789871B2 (ja) 2017-09-22 2025-12-22 リジェネロン・ファーマシューティカルズ・インコーポレイテッド グルカゴン様ペプチド１受容体アゴニストおよびそれらの使用

Also Published As

Publication number Publication date
JP2020534016A (ja) 2020-11-26
AU2018338178A1 (en) 2020-04-02
US20210283225A1 (en) 2021-09-16
JP7559112B2 (ja) 2024-10-01
IL304574A (en) 2023-09-01
IL304574B1 (en) 2025-04-01
CN111108117B (zh) 2024-08-06
WO2019060653A1 (en) 2019-03-28
US11045522B2 (en) 2021-06-29
AU2023223010B2 (en) 2025-12-04
CA3073964A1 (en) 2019-03-28
SG11202001637PA (en) 2020-03-30
CN111108117A (zh) 2020-05-05
US12090193B2 (en) 2024-09-17
IL273253B2 (en) 2024-07-01
AU2023223010A1 (en) 2023-11-09
AU2018338178B2 (en) 2023-06-08
JP2023071827A (ja) 2023-05-23
IL273253A (en) 2020-04-30
MY200364A (en) 2023-12-21
CN118955732A (zh) 2024-11-15
US11779633B2 (en) 2023-10-10
EA202090649A1 (ru) 2020-06-29
JP7789871B2 (ja) 2025-12-22
KR102696518B1 (ko) 2024-08-21
MX2020002977A (es) 2020-11-06
EP3684793A1 (en) 2020-07-29
IL304574B2 (en) 2025-08-01
US20240024428A1 (en) 2024-01-25
US20190091296A1 (en) 2019-03-28
JP2024178255A (ja) 2024-12-24
MY207828A (en) 2025-03-21
KR20200054303A (ko) 2020-05-19
US20250000949A1 (en) 2025-01-02
IL273253B1 (en) 2024-03-01
ZA202001167B (en) 2024-06-26

Similar Documents

Publication Publication Date Title
JP7789871B2 (ja) グルカゴン様ペプチド１受容体アゴニストおよびそれらの使用
JP7759417B2 (ja) レプチン受容体を活性化させる抗原結合タンパク質
JP2021090449A (ja) 抗−ａｎｇｐｔｌ８抗体及びその使用
JP7420730B2 (ja) 代謝機能不全または低レプチン血症の治療に使用するためのレプチン受容体アゴニスト性抗体
AU2017363143B2 (en) Methods of treating obesity with anti-ANGPTL8 antibodies
JP2025532651A (ja) 肥満、糖尿病および肝機能障害を処置する方法
WO2025180387A1 (en) Super long-lasting glp1 or glp1/gip analogue drugfor type-2 diabetes and obesity
CN114980916A (zh) 用于2型糖尿病的长效glp1类似物药物
EA045412B1 (ru) Агонисты рецептора глюкагоноподобного пептида 1 и их применения
HK40072673A (en) Antigen-binding proteins that activate the leptin receptor
HK1254862B (en) Antigen-binding proteins that activate the leptin receptor

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210909

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220722

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220809

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20221109

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221205

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230131

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230302

R150 Certificate of patent or registration of utility model

Ref document number: 7239566

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150